Looking Ahead in Complement-Mediated Kidney Diseases: What Clinical Questions Do Current Trials Aim to Answer

Did you know that, if left untreated, between 30% and 50% and up to 30% of patients with C3G and IgAN, respectively, will progress to end-stage kidney disease in 10 years? Credit available for this activity expires: 5/30/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/992405?ecd=bdc_podcast_libsyn_mscpedu